FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:IGF2R-TCP1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: IGF2R-TCP1
FusionPDB ID: 38554
FusionGDB2.0 ID: 38554
HgeneTgene
Gene symbol

IGF2R

TCP1

Gene ID

3482

6950

Gene nameinsulin like growth factor 2 receptort-complex 1
SynonymsCD222|CI-M6PR|CIMPR|M6P-R|M6P/IGF2R|MPR 300|MPR1|MPR300|MPRICCT-alpha|CCT1|CCTa|D6S230E|TCP-1-alpha
Cytomap

6q25.3

6q25.3

Type of geneprotein-codingprotein-coding
Descriptioncation-independent mannose-6-phosphate receptor300 kDa mannose 6-phosphate receptorCI Man-6-P receptorIGF-II receptorM6P/IGF2 receptorinsulin-like growth factor II receptorT-complex protein 1 subunit alphaT-complex protein 1, alpha subunitt-complex 1 proteintailless complex polypeptide 1
Modification date2020031520200313
UniProtAcc

P11717

Main function of 5'-partner protein: FUNCTION: Mediates the transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes (PubMed:2963003, PubMed:18817523). Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex (PubMed:2963003, PubMed:18817523). The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer (PubMed:18817523). This receptor also binds IGF2 (PubMed:18046459). Acts as a positive regulator of T-cell coactivation by binding DPP4 (PubMed:10900005). {ECO:0000269|PubMed:10900005, ECO:0000269|PubMed:18046459, ECO:0000269|PubMed:18817523, ECO:0000269|PubMed:2963003}.		.
Ensembl transtripts involved in fusion geneENST idsENST00000356956, ENST00000475584, 
ENST00000392168, ENST00000420894, 
ENST00000544255, ENST00000546023, 
ENST00000321394, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score23 X 16 X 11=40486 X 6 X 3=108
# samples 256
** MAII scorelog2(25/4048*10)=-4.01720929003222
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(6/108*10)=-0.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: IGF2R [Title/Abstract] AND TCP1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: IGF2R [Title/Abstract] AND TCP1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)IGF2R(160483651)-TCP1(160205099), # samples:1
Anticipated loss of major functional domain due to fusion event.IGF2R-TCP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
IGF2R-TCP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
IGF2R-TCP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
IGF2R-TCP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:160483651/chr6:160205099)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across IGF2R (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across TCP1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000356956IGF2Rchr6160483651+ENST00000321394TCP1chr6160205099-536638186148181585

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000356956ENST00000321394IGF2Rchr6160483651+TCP1chr6160205099-0.0001735740.9998265

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for IGF2R-TCP1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
IGF2Rchr6160483651TCP1chr616020509938181252WRTVEACPVVRVEGMPKRIVNAKIAC

Top

Potential FusionNeoAntigen Information of IGF2R-TCP1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
IGF2R-TCP1_160483651_160205099.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
IGF2R-TCP1chr6160483651chr61602050993818HLA-B08:09EGMPKRIV0.99860.61661220
IGF2R-TCP1chr6160483651chr61602050993818HLA-B27:05VRVEGMPKR0.99870.5659918
IGF2R-TCP1chr6160483651chr61602050993818HLA-A30:08VVRVEGMPK0.99680.8415817
IGF2R-TCP1chr6160483651chr61602050993818HLA-B27:14VRVEGMPKR0.99860.589918
IGF2R-TCP1chr6160483651chr61602050993818HLA-B27:03VRVEGMPKR0.95660.59918
IGF2R-TCP1chr6160483651chr61602050993818HLA-B27:10VRVEGMPKR0.9970.7976918
IGF2R-TCP1chr6160483651chr61602050993818HLA-A30:01VVRVEGMPK0.99660.9187817

Top

Potential FusionNeoAntigen Information of IGF2R-TCP1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
IGF2R-TCP1_160483651_160205099.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
IGF2R-TCP1chr6160483651chr61602050993818DRB1-0828VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1102VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1103VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1106VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1113VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1116VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1118VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1121VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1121PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1125VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1136VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1141VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1142VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1147VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1148VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1155VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1157VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1159VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1163VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1165VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1167VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1170VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1176VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1184VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1185VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1192VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1192PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1204VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1204PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1209VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1209PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1220VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1220PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1301VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1304VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1306VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1308VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1309VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1315VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1317VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1318VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1319VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1320VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1322VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1324VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1327VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1332VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1335VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1343VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1343PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1348VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1351VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1352VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1353VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1354VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1354PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1354VRVEGMPKRIVNAKI924
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1354CPVVRVEGMPKRIVN621
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1357VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1359VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1361VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1364VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1368VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1369VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1370VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1371VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1372VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1375VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1376VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1377VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1377PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1378VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1379VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1380VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1383VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1384VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1387VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1391VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1392VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1393VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1398VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1412VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1416VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1416PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1429VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1429PVVRVEGMPKRIVNA722
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1437VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1474VVRVEGMPKRIVNAK823
IGF2R-TCP1chr6160483651chr61602050993818DRB1-1481VVRVEGMPKRIVNAK823

Top

Fusion breakpoint peptide structures of IGF2R-TCP1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
906CPVVRVEGMPKRIVIGF2RTCP1chr6160483651chr61602050993818

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of IGF2R-TCP1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN906CPVVRVEGMPKRIV-7.2863-7.4808
HLA-B14:023BVN906CPVVRVEGMPKRIV-5.53924-6.29374
HLA-B52:013W39906CPVVRVEGMPKRIV-6.8421-7.0366
HLA-B52:013W39906CPVVRVEGMPKRIV-5.96593-6.72043
HLA-A11:014UQ2906CPVVRVEGMPKRIV-6.46121-7.21571
HLA-A11:014UQ2906CPVVRVEGMPKRIV-5.63558-5.83008
HLA-A24:025HGA906CPVVRVEGMPKRIV-8.14669-8.34119
HLA-A24:025HGA906CPVVRVEGMPKRIV-5.49112-6.24562
HLA-B44:053DX8906CPVVRVEGMPKRIV-7.19938-7.39388
HLA-B44:053DX8906CPVVRVEGMPKRIV-6.06675-6.82125
HLA-A02:016TDR906CPVVRVEGMPKRIV-7.00045-7.19495

Top

Vaccine Design for the FusionNeoAntigens of IGF2R-TCP1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
IGF2R-TCP1chr6160483651chr61602050991220EGMPKRIVAAGGCATGCCCAAGAGAATCGTAA
IGF2R-TCP1chr6160483651chr6160205099817VVRVEGMPKTTGTCAGAGTGGAAGGCATGCCCAAGA
IGF2R-TCP1chr6160483651chr6160205099918VRVEGMPKRTCAGAGTGGAAGGCATGCCCAAGAGAA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
IGF2R-TCP1chr6160483651chr6160205099621CPVVRVEGMPKRIVNGTCCCGTTGTCAGAGTGGAAGGCATGCCCAAGAGAATCGTAAATG
IGF2R-TCP1chr6160483651chr6160205099722PVVRVEGMPKRIVNACCGTTGTCAGAGTGGAAGGCATGCCCAAGAGAATCGTAAATGCAA
IGF2R-TCP1chr6160483651chr6160205099823VVRVEGMPKRIVNAKTTGTCAGAGTGGAAGGCATGCCCAAGAGAATCGTAAATGCAAAAA
IGF2R-TCP1chr6160483651chr6160205099924VRVEGMPKRIVNAKITCAGAGTGGAAGGCATGCCCAAGAGAATCGTAAATGCAAAAATTG

Top

Information of the samples that have these potential fusion neoantigens of IGF2R-TCP1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADIGF2R-TCP1chr6160483651ENST00000356956chr6160205099ENST00000321394TCGA-BR-A4PD-01A

Top

Potential target of CAR-T therapy development for IGF2R-TCP1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to IGF2R-TCP1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to IGF2R-TCP1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource